Low-dose IL-2 therapy has been evaluated for the treatment of numerous autoimmune conditions. This study reports the outcomes of a phase 2, randomised, placebo-controlled trial evaluating the efficacy and safety of low-dose IL-2 for the treatment of systemic lupus erythematosus (SLE).
- Xia Zhang
- Ruiling Feng
- Jing He